Pfizer Receives Breakthrough Therapy Designation from FDA for PF06651600 an oral JAK3 Inhibitor for the Treatment of Patients with Alopecia Areata

Phase II data accepted for latebreaker news session at 2018 EADV Congress Pfizer Inc. NYSEPFE today announced its investigational oral Janus kinase 3 JAK3 inhibitor PF06651600 received Breakthrough Therapy designation from ...